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Heparan sulfate (HS) binds and modulates the transport and
activity of a large repertoire of regulatory proteins. The HS
phage display antibodies are powerful tools for the analysis of
native HS structure in situ; however, their epitopes are not well
defined. Analysis of the binding specificities of a set of HS
antibodies by competitive binding assays with well defined
chemically modified heparins demonstrates that O-sulfates are
essential for binding; however, increasing sulfation does not
necessarily correlate with increased antibody reactivity. IC50
values for competition with double modified heparins were not
predictable from IC50 values with corresponding singly modi-
fied heparins. Binding assays and immunohistochemistry re-
vealed that individual antibodies recognize distinct epitopes and
that these are not single linear sequences but families of structur-
ally similar motifs in which subtle variations in sulfation and con-
formationmodify the affinity of interaction.Modeling of the anti-
bodies demonstrates that they possess highly basic CDR3 and
surroundingsurfaces,presentinganumberofpossibleorientations
for HS binding. Unexpectedly, there are significant differences
between the existence of epitopes in tissue sections and observed
in vitro in dot blotted tissue extracts, demonstrating that in vitro
specificity does not necessarily correlate with specificity in situ/
vivo. The epitopes are therefore more complex than previously
considered. Overall, these data have significance for structure-ac-
tivity relationships of HS, because the model of one antibody rec-
ognizing multiple HS structures and the influence of other in situ
HS-binding proteins on epitope availability are likely to reflect the
selectivity of manyHS-protein interactions in vivo.
HS2 belongs to the glycosaminoglycan family of polysaccha-
rides and can be considered themost information-rich biopoly-
mer in nature. HS chains consist of repeating -D-glucuronic
acid and GlcNAc units, which are subject to enzymatic post-
polymeric modification by N-deacetylation and N-sulfation of
GlcNAc,O-sulfation at various positions, and epimerization of
D-glucuronic acid to its C-5 epimer, iduronic acid. HS biosyn-
thetic enzymes do not act upon every potential site within a
chain, resulting in chainswith a high level of structural diversity
and a distinct domain structure, with regions of unmodified
saccharides (N-acetyl domains) and highly modified sacchar-
ides (N-sulfated domains) flanked by regions of alternating
modified and unmodified disaccharides (transition orN-acetyl/
N-sulfated domains) (1–4). HS chains are usually attached
to core proteins, forming HS proteoglycans, and these proteogly-
cans represent one of the major components of most metazoan
cell surfaces and extracellular matrices. Here, they control cell-
cell and cell-matrix communication by association with a large
repertoire of regulatory proteins (5), including growth factors,
morphogens, extracellular matrix components, enzymes, cell
adhesion molecules, and cytokines. It is through these interac-
tions with proteins that HS exerts its role in numerous biolog-
ical processes during embryogenesis, development, and adult
homeostasis, largely by regulating transport and/or effector
functions of its protein ligands.
The structure of HS is dynamic and is directed by the cellular
environment and physiology, i.e. tissue/cell type, state of differ-
entiation and growth, and pathology. Distinct cellular sources
have been shown to display a range ofHS chain lengths, domain
structures, and sulfation (1, 6–10). Native HS is therefore
highly diverse, with each cell synthesizing an array of HS chains
of different lengths and structures with a variety of modifica-
tions and chain domain organization. HS should therefore not
be classed as a single entity but rather as a family of structurally
related but highly diverse molecules with a range of functional
effects. The mechanisms regulating HS biosynthesis and the
resulting structure of HS are poorly understood; thus, the
precise composition of native chains is difficult to establish.
Nucleic acids can be amplified and quantified by PCR and local-
ized by in situ hybridization; there are no such methods for
analyzing the minute quantities of HS structures in a tissue.
Tissue HS is usually structurally analyzed following extraction
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and purification; the inherent averaging of this approach, how-
ever, limits the information to the overall assessment of mixed
populations of HS structures and the loss of all spatial informa-
tion. Monoclonal antibodies directed toward glycosaminogly-
cans such as chondroitin sulfate/dermatan sulfate and keratan
sulfate are available that enable the localization of specific gly-
cosaminoglycan epitopes to be identified in tissues (11–17). In
contrast, HS-specific monoclonal antibodies are relatively lim-
ited, with only a few available (18–21). To circumvent the dif-
ficulties of analyzing tissue HS in situ, HS-specific single chain
variable fragment (scFv) antibodies have been generated by
phage display technology, which enables the detection of HS
glycosaminoglycan structures in situ (22–24). These antibodies
have been used to probe HS in a variety of tissues, including
kidney (22, 24, 25), skeletal muscle (23, 26, 27), spleen (28),
pancreas (29), fetal lung (30), and adult lung (31), and in disease,
such as metastatic malignant melanoma (32). However, their
application is complicated by the fact that they are raised
against heterogeneous native heparin and HS chains, and con-
sequently the exact structures they recognize within the
polysaccharide are unknown. This hinders further application
of the antibodies and interpretation of tissue staining patterns.
To gain insights into the specificity of these valuable analytical
tools, the binding characteristics and epitope structures recog-
nized by a panel of six scFvHS antibodies were examined. Anti-
body epitopes were probed in situ using immunohistochemis-
try and dot blotting of embryonic rat lungs, because the
development of the lung represents one of the core models of
mammalian organogenesis, and its functional transition post-
partum is a key event in mammalian physiology. In addition,
modeling of the antibody structures and competition binding
assays with various heparin analogues were used to determine
antibody binding specificities in vitro. The results show that HS
phage display antibodies all share a similar, largely basic struc-
ture and recognize distinct HS epitopes that are structurally
complex. Analysis of antibody binding specificities also pro-




Rabbit anti-VSV-G tag IgG was from Abcam, (Cambridge,
UK), mouse anti-His tag IgG was from Sigma-Aldrich, HRP-
conjugated sheep anti-mouse IgGwas fromGEHealthcare, and
fluorescein isothiocyanate-conjugated goat anti-rabbit IgGwas
from Sigma-Aldrich. Bovine serum albumin (BSA) was from
Sigma-Aldrich, and nonfat dry milk powder was from Tesco,
UK. SuperSignal West Dura Extended Duration Substrate and
Hyperfilm ECLwere fromGEHealthcare. Heparinase enzymes
were purchased from IBEXTechnologies Inc., porcinemucosal
heparan sulfate (PMHS) was a gift from Organon (Oss, Neth-
erlands), and heparin (sodium salt) was purchased from Celsus
Laboratories Inc. Protease inhibitor mixture was from Roche
Applied Science. Chemicallymodified heparinswere a gift from
Dr. E. A. Yates (University of Liverpool) and prepared as
described previously (33). Heparin oligosaccharides were a gift
from Y. A. Ahmed (University of Liverpool). EZ-LinkTM NHS-
LC-biotin was from Pierce, streptavidin was from Promega,
and Sephadex G-25 gel filtration column was purchased from
Sigma-Aldrich. Maxisorp 96-well microtiter plates were pur-
chased from Nunc (Fisher), and o-phenylenediamine (o-phe-
nylenediamine substrate) was from Dako Ltd. (Ely, UK).
Immunohistochemistry
Lungs from Sprague-Dawley rats (Charles River Ltd, Mar-
gate, UK) were harvested at embryonic days (E) 15.5 and 17.5 of
gestation and fixed with 4% (w/v) paraformaldehyde in phos-
phate-buffered saline (PBS), pH 7.4. The lungs were washed in
PBS, cryoprotected with 20% (w/v) sucrose in PBS, and gelatin-
embedded (7.5% (w/v) gelatin, 15% (w/v) sucrose in PBS) before
being covered in Cryo-M-Bed (Bright, Huntingdon, UK) and
snap frozen at 40 °C. The lung sections were cut at 8 m and
mounted onto chrome alum gel slides for storage at 40 °C.
Tissue sections were blocked with 10% (v/v) goat serum in PBS
and incubated overnight at 4 °C with HS scFv antibodies,
diluted 1/5 in 1% (v/v) goat serum in PBS. Bound antibody was
detected with rabbit VSV-G tag antibody diluted 1/200 in 1%
(v/v) goat serum inPBS, followedby fluorescein isothiocyanate-
conjugated goat anti-rabbit IgG. The controls were omission of
HS antibody or treatment of tissue sections with heparinase III
(EC 4.2.2.8) (5 milliunits/ml in 100 mM sodium acetate, 0.1 mM
calcium acetate, 50 g/ml BSA, pH 7.0) for 2 h at 37 °C, prior to
antibody incubation to remove HS epitopes.
Dot Blotting of Lung Extracts
Lungs from Sprague-Dawley rats (Charles River) were har-
vested at E15.5, E17.5, E19.5, and E21.5 of gestation and imme-
diately homogenized on ice with 50 mM Tris-HCl, pH 7.4, 150
mMNaCl, 2% (w/v) SDS, and protease inhibitor mixture (1 tab-
let/10 ml buffer). Because earlier gestation stage lungs are
smaller, a higher number of E15.5 lungs were used to prepare
lung extract samples compared with E21.5 lungs. This ensured
similar ratios of tissue weight:volume homogenization buffer.
The homogenates were centrifuged at 4 °C at 14,000 rpm for 10
min, and supernatants were collected. Each supernatant was
then standardized for protein concentration. Lung extracts (10
l) were blotted onto nitrocellulose membrane, and endoge-
nous peroxidase was quenched with 0.6% (v/v) hydrogen per-
oxide in PBS. Themembranes were blockedwith 5% (w/v) non-
fat dried milk in PBS containing 0.2% (v/v) Tween 20 (PBST).
HS antibodies were diluted 1/10 in 5% (w/v) milk in PBST, and
the membranes were incubated overnight at 4 °C. Bound anti-
bodies were detected with mouse anti-His tag IgG, diluted
1/20,000 followed by HRP-conjugated sheep anti-mouse IgG,
diluted 1/2000. Afterwashes in PBST and finally PBS, themem-
branes were incubation in SuperSignal West Dura extended
duration substrate for 5 min and exposed to Hyperfilm ECL.
The controls were omission of HS antibody, omission of HS
antibody, and anti-His tag antibody or treatment of lung
extracts with heparinase I, II, and III (all 5 milliunits/200 l of
extract in 100 mM sodium acetate, 0.1 mM calcium acetate, 50
g/ml BSA, pH 7.0) for 4 h at 37 °C to remove epitopes prior to
blotting lung extract.
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Molecular Modeling of Antibody Three-dimensional Structure
and Surface Electrostatic Potentials
Antibody light and heavy chain sequences were aligned with
known sequences and submitted to web antibody modeling, an
online resource hosted by The Centre for Protein Analysis and
Design at the University of Bath. This is specifically tailored to
construct three-dimensional models of antibody Fv sequences.
The resulting models were then viewed in a Swiss-PDB viewer.
Competition Binding Assays and Enzyme-linked
Immunosorbent Assay
Biotinylation of Heparan Sulfate—N-Hydroxysuccinimide
amino caproate biotin (NHS-LC-biotin) (25l of a 50mM solu-
tion in dimethyl sulfoxide) was added to 5 mg of PMHS in 500
l of distilled water and allowed to react overnight at room
temperature. A further 25l of NHS-LC-biotinwas added after
this time. Biotinylated polysaccharide was separated from
unconjugated biotin on a Sephadex G-25 gel filtration column,
with the absorbance monitored at 280 nm to identify fractions
containing biotinylatedHS. In this way, PMHSwas biotinylated
internally within the polysaccharide chain at rare N-unsubsti-
tuted glucosamines. PMHS is estimated to contain 1.2–7.5%
free amines (34), equating to 1–2 biotinylation sites/HS chain;
thus, attachment to microtitre plates will be made at a
restricted number of sites/chain.
Enzyme-linked Immunosorbent Assay—Three g/ml strepta-
vidin in 0.1 M Na2CO3HCO3 (pH 9.6) was incubated for 16 h at
4 °C in Maxisorp 96-well microtiter plates. The plates were
blocked with 1% (w/v) BSA in PBS for 2 h at room temperature,
washed with PBST (0.05% (v/v) Tween 20), and then incubated
with biotinylated PMHS (75 g/ml) in 1% (w/v) BSA, PBST for
2 h at room temperature. The plates were washed with PBST,
and 15 l of antibody was added to wells with 15 l of compet-
itor saccharide (heparin dp2–dp20 oligosaccharides or chemi-
cally modified heparins) and incubated overnight at 4 °C. The
antibody dilutions were determined in a titer and were used at
final concentrations of; HS3B7V 1/5, HS4E4V 1/15, HS3A8V
1/20, AO4B08V 1/15, EV3C3V 1/15, and EW4G1V 1/2. Com-
petitor saccharides (10mg/ml in distilledwater) were diluted in
2% BSA in PBST (0.1% Tween 20) to the required concentra-
tions. For the positive control, antibodywas added towells with
2% BSA in PBST without competitor saccharide. The plates
were washed in PBST and incubated with mouse anti-VSV-G
IgG, clone P5D4, diluted 1/100 for 1 h, followed by HRP-con-
jugated sheep anti-mouse IgG, diluted 1/1000. After washing in
PBST, the plateswere developedwith o-phenylenediamine sub-
strate, and A490 values were measured using a microtiter plate
reader.
RESULTS
Six antibodies were chosen on the basis that they had been
raised against HS/heparin from a variety of tissue sources and
encompassed a broad spectrum of antibody structures. Their
selection contained two pairs of antibodies that shared an iden-
tical framework structure and therefore only differed in the VH
CDR3 sequence (HS4E4V/HS3A8V and EV3C3V/EW4G1V).
The two remaining antibodies had distinct framework struc-
tures and unique VH CDR3 sequences (Table 1).
Anti-HS scFv Antibodies Identify Distinct Epitopes in Fetal
Rat Lungs—HS phage display antibodies displayed different
patterns of immunoreactivity in embryonic rat lungs, indicat-
ing distinct HS epitopes (Fig. 1). All of the antibodies showed
strong immunoreactivity to airway epithelial basement mem-
branes; one antibody, HS3B7V, exclusively labeled epithelial
basement membranes in the lungs and failed to stain mesen-
chymal or epithelial cells (Fig. 1C, panel 2). HS3A8V and
EV3C3V showed similar patterns of immunohistochemistry in
E15.5 rat lungs, labeling airway epithelium, underlying base-
ment membranes and the surrounding mesenchyme (Fig. 1A,
panels 1 and 2). However, at E17.5, staining by these two anti-
bodies differed, most notably in the lung mesenchyme;
HS3A8V staining remained strong throughout the mesen-
chyme (Fig. 1B, panel 1), whereas a gradient of mesenchymal
EV3C3V staining was observed, with the highest levels of
immunoreactivity around the smaller developing airways (Fig.
1B, panel 2). EW4G1V and AO4B08V also demonstrated
equivalent patterns of staining in E15.5 rat lungs, both showing
strong labeling of epithelial basement membranes and weak
labeling of the surrounding mesenchyme (Fig. 1A, panels 3 and
4). In E17.5 lungs, however, staining with the two antibodies
was distinct; EW4G1V mesenchymal staining remained weak
(Fig. 1B, panel 3), whereas AO4B08V mesenchymal staining
increased significantly (Fig. 1B, panel 4). The final antibody,
HS4E4V showed a unique pattern of immunoreactivity in E15.5
lungs, labeling epithelial basement membranes and areas of
mesenchyme surrounding smaller distal airways (Fig. 1C, panel
1). Immunohistochemical analysis of antibody binding specific-
ities thus indicated unique HS epitope expression.
To gain further biochemical insight into the expression of
antibody-binding sites, we examined the presence of epitopes
biochemically by dot blotting tissue extracts from developing
rat lungs and probing with HS antibodies. In many cases the
epitopeswere identified in lung extracts at varying levels during
development that correlated with the relevant immunochem-
istry data. Surprisingly, however, one antibody, HS4C3V, failed
to label developing rat lungs in situ (data not shown), whereas
the epitope was clearly identified in vitro in dot blotted lung
extracts (Fig. 2). In addition, alongside the major difference in
recognition of the HS4C3V epitope, a number of more subtle
discrepancies between the in situ and in vitro detection of
epitopes were observed. Levels of the AO4B08V epitope were
high in E15.5 lung extracts and increased further in E17.5
extracts (Fig. 2), whereas in situ the epitopewas present at a low
level at E15.5 and significantly increased in E17.5 lungs (Fig. 1,A
TABLE 1
HS phage display antibodies
Heavy chain variable genes (VH) and gene segments (DP) for each antibody are
shown, together with heavy chain CDR-3 sequences, which are considered to be
major determinants in antibody specificity. The source of HS against which the
antibodies were raised and important references are also shown.
Clone VH DP CDR3 Selected against Ref.
HS3B7V 1 3 SRKTRKPFMRK Bovine kidney HS 24
AO4BO8V 3 47 SLRMNGWRAHQ Mouse skeletal muscle HS 23
HS4E4V 3 38 HAPLRNTRTNT Bovine kidney HS 23
HS3A8V 3 38 GMRPRL Bovine kidney HS 23
EV3C3V 3 42 GYRPRF Human lung HS 24
EW4G1V 3 42 GARLKR Porcine intestine mucosal
heparin
32
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and B, panels 4). Conversely, EV3C3V epitope levels observed
in dot blots were very low at E15.5 and increased significantly at
E17.5 (Fig. 2), whereas in situ the epitope was present at a con-
sistently high level throughout development (Fig. 1, A and B,
panels 2). These observations are significant, as they highlight
an important difference between the presence and availability
of epitopes in a native environment in situ compared with an in
vitro environment, i.e. in tissue extracts. In the latter, HS chains
may be stripped of the majority of their protein partners (e.g.
because of detergent in homogenization buffer), whereas in
situ, bound proteins could be associated with HS chains and
modify antibody binding.
Three-dimensional Modeling of scFv anti-HS Antibody
Structures—The antibodies consisted of a heavy chain (VH) and
a light chain variable domain (VL), which are connected by a
polypeptide linker. Within both of
these domains were three hyper-
variable regions, termed comple-
mentarity determining regions
(CDRs), which form the antigen-
binding site. All of the antibodies
shared an identical VL chain but
showed differences in their VH
chains.
Two pairs of antibodies, HS4E4V/
HS3A8V and EV3C3V/EW4G1V,
were encoded by identical gene seg-
ments belonging to the VH3 gene
family, and consequently, their
amino acid sequences were identi-
cal apart from their CDR3 (Table 1).
AO4B08V was encoded by a differ-
ent gene segment (DP47) of the VH3
gene family, resulting in minor vari-
ations in the heavy chain amino acid
sequence, as well as a unique CDR3
(Table 1). HS3B7V was distinct
from the other antibodies, originat-
ing from a different VH gene family
altogether (VH1), resulting in a
more diverse heavy chain sequence
and more obvious variations in
structure and surface electrostatic
potential compared with the other
five antibodies. The surface electro-
static potentials of the antibodies
have not been examined before and
were therefore modeled here. Mod-
eling revealed a large basic area
on the surface of all antibodies,
expected to be a significant media-
tor of interactions with polyanionic
heparin/HS (Figs. 3 and 4 and sup-
plemental Figs. S1–S4). However,
the large area of basic residues dom-
inating the surface of the antibodies
clearly providedmore than one pos-
sibility for the binding orientation of
HS. Measurement of the potential binding axes for heparin/HS
revealed that lengths of between 2 and 4 nm can be accommo-
dated (Figs. 3 and 4 and supplemental Figs. S1–S4), corre-
sponding to a dp4–dp10 heparin/HS sequence, because a dis-
accharide measured 0.8 nm in length (35). Interestingly, on
the surface of HS3B7V, however, the basic patch was compar-
atively smaller than the other antibodies, and there was also a
higher proportion of acidic regions on its surface (Fig. 4). The
binding axis for heparin/HSwould, therefore, be expected to be
more restricted in this case than with the other antibodies.
Binding Specificities of HS scFv Antibodies—Competition
assays were used to evaluate the ability of heparin oligosaccha-
rides of various lengths and with various selective sulfation
modifications (Table 2) to compete with immobilized PMHS
for binding of six HS antibodies. Chemically modified heparin
FIGURE 1. HS phage display antibodies identify distinct HS structures in embryonic rat lung. In E15.5 lungs,
HS3B7V exclusively labels epithelial basement membranes and HS4E4V labels basement membranes together with
areas of mesenchyme surrounding smaller distal airways. HS3A8V and EV3C3V both label epithelial cells, underlying
basement membranes and surrounding mesenchyme in E15.5 lungs; however, at E17.5, staining differs. HS3A8V
staining remains strong throughout E17.5 lung mesenchyme, whereas EV3C3V staining becomes more restricted to
areas of mesenchyme adjacent to smaller airways. EW4G1V and AO4B08V also show equivalent patterns of staining
in E15.5 lungs, strongly labeling epithelial basement membranes and labeling the surrounding mesenchyme more
weakly. However, in E17.5 lungs, EW4G1V mesenchymal staining remains weak, whereas AO4B08V mesenchymal
staining increases. Immunohistochemistry with individual antibodies is therefore unique, indicating distinct
epitopes. E15.5 and E17.5 rat lungs were probed with HS antibodies followed by rabbit VSV-G tag antibody and
fluorescein isothiocyanate-conjugated goat anti-rabbit IgG. The negative controls were omission of HS antibody or
digestion of HS with heparinase prior to antibody incubation. All of the images are at the same magnification. aw,
airway; mes, mesenchyme; epi, epithelium; bm, basement membrane.
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oligosaccharides were used as model binding competitors,
because their sulfation patterns are virtually homogeneous, and
they have been structurally characterized (36, 37). This allows
systematic “footprinting” of the effects of altered sulfation pat-
terns (41) and allows for interpretation of binding data. HS
oligosaccharides, which are generally more heterogeneous,
could not be characterized as rigorously or systematically. Suf-
ficient numbers of pure structurally defined HS oligosaccha-
rides are not currently available, making heparin oligosaccha-
rides the most useful model structures available at present to
systematically analyze antibody binding specificities. Relative
binding affinities of the antibodies and heparin analogues were
evaluated by determining IC50 values, defined as the concentra-
tion of competitor that inhibits antibody binding to immobi-
lized HS by 50%.
FIGURE 2. Dot blot analysis of HS epitopes in E15. 5–21.5 fetal rat lung
extracts identified differences between in situ and in vitro detection of
epitopes. Lung extracts (10 l) were blotted onto nitrocellulose membrane
and probed with HS antibodies as described under “Experimental Proce-
dures.” Bound antibodies were detected via their polyhistidine (His) tag with
mouse anti-His-tag IgG, followed by HRP-conjugated sheep anti-mouse IgG.
The data are representative of two independent blots. A, the top left panel
shows the arrangement of four extracts from E15.5, E17.5, E19.5, and E21.5
fetal lungs. The remaining panels are labeled with the relevant probe HS
antibody. B, control data showing background binding after digestion of HS
via treatment of lung extracts with a mixture of heparinases I, II, and III (all 5
milliunits/200 of l extract) prior to blotting onto membrane and probing
with antibodies (panels correspond to those in shown in A). C, control probing
of blots with secondary anti-His tag and tertiary HRP anti-mouse only (2nd/
3rd Ab) or tertiary HRP anti-mouse (3rd Ab) only. Low background immunore-
activity was noted for heparinase-treated lung extract blots; this is likely to
reflect reduced enzyme activity in the presence of SDS (data not shown). Ab,
antibody.
FIGURE 3. Proposed model and surface electrostatic potential of HS4E4V
from four perspectives. A large proportion of basic residues are observed on
the surface of the antibody, which will interact with HS and heparin. Two
possible HS-binding axes and their lengths are shown. The structure of
HS4E4V is extremely similar to HS3A8V, EV3C3V, EW4G1V, and AO4B08V,
shown in supplemental Figs. S1–S4. Regions of positive surface charge are
represented in blue, and regions of negative charge are in red, whereas neu-
tral areas are white.
FIGURE 4. Proposed model and surface electrostatic potential of HS3B7V
from four perspectives. Two possible HS binding axes and their lengths are
shown. Note the smaller proportion of basic residues and higher number of
acidic patches on the surface of this antibody compared with the others
(Compare with HS4E4V in Fig. 2 and other antibodies described in supple-
mental Figs. S1–S4). Regions of positive surface charge are represented in
blue, and regions of negative charge are in red, whereas neutral areas are
white.
TABLE 2
Chemically modified heparin structures
The letter I stands for iduronate, and A stands for amino sugar (glucosamine).
Analogue Predominantstructure IdoC2 GlcC6 GlcC2
Heparin I2SA6SNS SO3 SO3 SO3
De-N-sulfated I2SA6SNAc SO3 SO3 COCH3
De-2-O-sulfated I2OHA6SNS OH SO3 SO3
De-6-O-sulfated I2SA6OHNS SO3 OH SO3
De-N/de-2-O-sulfated I2OHA6SNAc OH SO3 COCH3
De-N/de-6-O-sulfated I2SA6OHNAc SO3 OH COCH3
Only N-sulfated I2OHA6OHNS OH OH SO3
Fully de-N/O-sulfated I2OHA6OHNAc OH OH COCH3
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Minimal Length Heparin-binding Sites—At least a dp4 hep-
arin saccharide was required to compete for antibody-HS bind-
ing, with heparin disaccharides (dp2) showing little or no com-
petition. As heparin oligosaccharide length increased from dp4
to dp10, IC50 values progressively decreased, signifying improv-
ing competition (Fig. 5 and supplemental Fig. S5). This corre-
lates with the modeling data, which indicated that the basic HS
binding patch on the surface of the antibodies can accommo-
date between a dp4 and dp10 heparin oligosaccharide (Figs. 3
and 4 and supplemental Fig. S5). Binding of HS3A8V, HS4E4V,
and AO4B08V antibodies to immobilized HS was competed by
relatively high concentrations of dp4 heparin, and substantial
competitionwas observedwith heparin oligosaccharides of dp6
and above (Fig. 5,A, B, and E). Conversely, heparin dp4 showed
limited ability to compete for EV3C3V and EW4G1V binding;
these antibodies required a minimum of heparin dp6, with
more significant competition observed with heparin dp8 and
longer (Fig. 5, C and D). The
HS3B7V antibody showed a more
complicated binding profile, with
no significant competition with
dp2–dp8 heparins (Fig. 5F). Com-
petition was observed with heparin
dp10 but remained limited. Thus,
oligosaccharide length in the as-
say was extended to dp12-dp20
for HS3B7V. Heparin dp12-dp18
showed limited variation in competi-
tion,with IC50 values between3 and5
g/ml (Fig. 5F). Improved competi-
tion was observed with heparin dp20
(IC50 of 1.25 g/ml); however, full-
length heparin, with an IC50 of 0.06
g/ml, was still a 20-fold stronger
competitor for this antibody than
dp20 heparin. Intriguingly, molecular
modeling of this antibody revealed a
relatively smaller basic patch for hep-
arin/HS binding compared with the
other antibodies (Fig. 4), suggesting a
particularly unusual binding relation-
ship between this antibody and the
polysaccharide.
Involvement of Particular Struc-
tural Moieties in Antibody Binding—
Removal of all sulfate groups from
heparin or removal of all O-sulfates
abolished competition by the
polysaccharide for all antibodies,
emphasizing the importance of
O-sulfation in binding specificity
(Fig. 6). Individual removal of N-,
2-O-, or 6-O-sulfates from heparin
reduced competition for five of six
antibodies. The exception was
HS4E4V; although de-N-sulfation
of heparin reduced the competing
ability of the polysaccharide for
HS4E4V, removal of 2- or 6-O-sulfates fromheparin resulted in
a structure with 2-fold increased competition for HS4E4V (Fig.
6B). For the other five antibodies, the most significant reduc-
tion in competition was observed following removal of N- or
2-O-sulfates, with de-6-O-sulfation having less of an effect. Fur-
ther information was obtained from competition assays using
double modified heparin derivatives, i.e. with sulfates selec-
tively removed from two different positions. This is the first
time that these particular modified heparin polysaccharides
have been used to systematically explore antibody-HS interac-
tions and provide new and important insights into the binding
specificities of the antibodies. De-N-sulfated heparin addition-
ally de-2-O-sulfated or de-6-O-sulfated competed to variable
extents and generated intriguing results. First, the doublemod-
ified de-N/de-6-O-sulfated heparin was, in all cases, a weaker
competitor than de-N/de-2-O-sulfated heparin, and for three
of the antibodies (HS4E4V, HS3A8V, and EV3C3V), de-N/de-
FIGURE 5. IC50 values for the binding of HS antibodies to immobilized HS in the presence of heparin
oligosaccharides of various length and full-length heparin. PMHS was biotinylated and immobilized on
streptavidin-coated microtiter plates. Equilibrium binding of HS antibodies in the presence of heparin oligo-
saccharides, dp2– dp12 and full-length heparin (FL) was quantified at A490 using a VSV-G tag antibody (P5D4)
followed by HRP-conjugated anti-mouse antibody and o-phenylenediamine substrate. The range of heparin
oligosaccharides was extended to dp12– dp20 for HS3B7V. The IC50 values were calculated as the concentra-
tions of competitor saccharide required for 50% inhibition of antibody binding to immobilized HS. The values
are the means of triplicate samples, the error bars represent the S.E., and the data are representative of two
separate experiments. * denotes oligosaccharides unable to compete sufficiently to calculate an IC50.
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6-O-sulfated heparin did not com-
pete at all (Fig. 6,A–C). This is inter-
esting when compared with singly
de-2-O-sulfated or de-6-O-sulfated
heparins, where removal of 2-O-sul-
fates resulted in a weaker competi-
tor than removal of 6-O-sulfates.
The exception to this was HS4E4V,
forwhich de-2-O-sulfated and de-6-
O-sulfated heparins showed com-
parable competition (Fig. 6B). Sec-
ond, competition with the double
modified heparins was not simply
an additive result of the level of
competition achieved with the cor-
responding singly modified struc-
tures. For example, singly modified
de-N-sulfated and de-6-O-sulfated
heparinswere 30- and 6-foldweaker
competitors, respectively, than fully
sulfated heparin for HS3B7V,
whereas removal of both of these
sulfate species from heparin
resulted in a substantially weaker
competitor than might be expected,
with 1000-fold reduced competi-
tion (Fig. 6F). For a number of anti-
bodies, competition with double
modified heparins was comparable
with the corresponding singly mod-
ified heparins. For example, compe-
tition for EV3C3V was similar with
de-N/de-2-O-sulfated heparin and
singlymodified de-N-sulfated hepa-
rin with IC50 values of 90 and 75
g/ml, respectively (Fig. 6C). Simi-
larly, de-N/de-2-O-sulfated heparin
competed similarly to singly de-N-
sulfated heparin and de-2-O-sul-
fated heparin for EW4G1V with
IC50 values of 5.2, 4.8, and 3.3g/ml
(Fig. 6D). For a number of antibod-
ies, double modified heparins with
two sulfate species removed were
actually stronger competitors than
the corresponding singly modified
polysaccharides. For example,
de-N/de-2-O-sulfated heparinwas a
stronger competitor for HS3A8V
(IC50 of 270 g/ml) than singly de-
N-sulfated heparin (IC50 of 500
g/ml) (Fig. 6A). De-N/de-2-O-sul-
fated heparin, with an IC50 of 28
g/ml, was also a stronger compet-
itor for AO4B08V than its corre-
sponding singly modified heparins,
which had IC50 values of 240 g/ml
(de-N-sulfated heparin) and 70
FIGURE 6. IC50 values for the binding of HS antibodies to PMHS in the presence of competing chem-
ically modified heparins, unmodified heparin and HS. PMHS was biotinylated and immobilized on
streptavidin-coated microtiter plates. Equilibrium binding of HS antibodies in the presence of variable
concentrations of heparin, HS, and modified heparin derivatives was quantified at A490 using a VSV-G tag
antibody (P5D4) followed by HRP-conjugated anti-mouse IgG and o-phenylenediamine substrate. Modi-
fied heparins are: de-N-sulfated/N-acetylated heparin (NAc), de-2-O-sulfated heparin (de2O), de-6-O-sul-
fated heparin (de6O), de-N-sulfated/N-acetylated and de-2-O-sulfated heparin (de2ONAc), de-N-sulfated/
N-acetylated and de-6-O-sulfated heparin (de6ONAc), exclusively N-sulfated heparin (NS only), and
completely de-O/N-sulfated/N-acetylated (de2,6ONAc) IC50 values were then calculated as the concentra-
tion of competitor saccharide needed for 50% inhibition of antibody binding to immobilized HS. The
values are the means of triplicate samples, the error bars represent the S.E., and the data are representative
of two separate experiments. * denotes oligosaccharides unable to compete sufficiently to calculate
an IC50.
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g/ml (de-2-O-sulfated heparin) (Fig. 6F). The binding curves
are shown in supplemental Fig. S6.
DISCUSSION
The structural heterogeneity of HS renders characterization
of native HS chains difficult. HS phage display antibodies allow
nativeHS to be probed in situ, and immunohistochemical anal-
ysis of fetal rat lungs indicated that antibodies identify distinct
HS epitopes with a developmentally controlled pattern of
expression. However, a limitation of the antibodies is that the
exact HS structures recognized remain relatively undefined;
thus, a characterization of antibody binding specificities and
epitope structures was undertaken.
Antibody Surfaces Are Highly Basic, Providing Multiple Pos-
sible Binding Orientations—All of the antibodies exhibited a
clear trend of improved binding as heparin oligosaccharide
length increased. This was not surprising given the observed
high basicity of antibody surfaces, which will be increasingly
attracted toward the extending length of acidic oligo/polysac-
charide. As heparin chain length increased, long range electro-
static forces increased, which acts to maneuver the antibody
andpolysaccharide toward each other in a favorable orientation
for binding, increasing the probability of a productive binding
event, a phenomenon described as electrostatic steering (38,
39). The large basic area on the surface of the antibodies pro-
vides a number of possible orientations for HS/heparin to bind.
The highest affinity binding, however, will result from the inter-
action that has the largest intermolecular surface area, i.e. the
longest oligosaccharide of appropriate structure bound to the
longest basic axis of the antibody, with concomitant interac-
tions along the cognate molecular surfaces. The importance of
the VH CDR3 in determining binding specificity was evident by
distinct binding characteristics of antibodies whose amino acid
sequences differed only in the VH CDR3, i.e.HS4E4V/HS3A8V
and EV3C3V/EW4G1V (Table 1). However, the large area of
basicity of antibody surfaces suggests that regions flanking the
VH CDR3 within the antibody framework are also involved in
HS interactions, complicating epitope characterization. In
competition assays, most antibodies require a minimum of
dp4–dp6 heparin, except for HS3B7V, which required a longer
polysaccharide. Geometrically, for a heparin oligosaccharide of
dp12 or longer to bindHS3B7V, the polysaccharide would have
to wrap around the antibody, which is unlikely given the rela-
tively limited flexibility of the heparin glycosidic linkage (40). In
addition, the predicted model of HS3B7V revealed a smaller
basic patch on its surface compared with the other antibodies,
only able to accommodate between a dp4–dp10 heparin (Fig.
4). One possibility is that HS3B7V is not monomeric in solu-
tion, perhaps existing as a dimer with a bipartite binding site.
Alternatively, HS3B7V may require a rare structural motif in
heparin (e.g. an N-unsubstituted amine, 3-O-sulfated gluco-
samine, or a precise sequence arrangement), the frequency of
which would be anticipated to increase as oligosaccharide
length increases.
Antibody Epitope Structures Are Complex and Cannot Be
Characterized as Simple Linear HS Motifs—Previous attempts
to characterize anti-HS scFv antibody epitopes have, in the
majority of the cases, used a direct enzyme-linked immunosor-
bent assay approach, whereby test polysaccharides of various
structures are passively adsorbed to a surface and antibody
binding is measured directly (24, 31, 41). A weakness of this
method is that the structure of the different polysaccharides
may affect their immobilization to the surface, and immobili-
zationmustmask some structural groups; together these effects
will result in variations in surface coverage and exposed binding
structures, as suggested previously by Powell et al. (42). In con-
trast, competition enzyme-linked immunosorbent assay, used
here and in two previous studies (24, 43), uses a constant sur-
face of immobilizedHS or heparin and is therefore likely to be a
more objective measurement of antibody binding specificity.
Our binding assays also feature additional competitor polysac-
charides to those used in previous analyses, in particular, dou-
ble modified de-N/de-2-O-sulfated and de-N/de-6-O-sulfated
heparins, which have provided more revealing information on
antibody binding. Ideally, a large library of structurally defined
HS oligosaccharides would be used to evaluate antibody bind-
ing specificities. Although the generation of such libraries is
underway (44, 45), few HS oligosaccharides have so far been
sequenced (46–51) and given the yield of these oligosaccha-
rides, full structural characterization by NMR will only be pos-
sible in a very limited number of cases. This approach is there-
fore not yet feasible. In the interim, simplifiedmodel structures
generated by the uniform removal of specific sulfate groups
from heparin chains provide an invaluable tool, because they
aremore homogenous andhave been structurally characterized
(36, 37), allowing a systematic evaluation of antibody binding
specificity. The effect of a single alteration in structure, i.e.
removal of 6-O-sulfates, on antibody binding can bemonitored
and interpreted. In the binding assays performed here, sulfa-
tion, particularly O-sulfation, was shown to be essential for
antibody-HS interactions; however, binding appears to bemore
intricate than simply relying on sulfates alone, with increasing
levels of saccharide sulfation not necessarily correlating with
increased antibody reactivity. These data on the effects of selec-
tive removal of sulfate groups are clearly not consistent with
recognition of single linear epitopes by these antibodies,
because if the latter was the case, more dramatic effects on
binding would be expected with the loss of one or more sulfate
groups. In more than one instance, the IC50 values for compe-
tition with double modified heparins was not predictable from
the IC50 values of competition with the corresponding singly
modified heparins. The most likely explanation is that the con-
formation of the sugar is particularly significant in determining
antibody binding specificity and affinity.
A major area of flexibility within HS chains are iduronic acid
residues, which can adopt more than one conformation within
HS chains, 1C4 chair, and 2S0 skew boat conformers (52) and
may play a role in the generation of antibody epitopes in situ.
The balance of iduronic acid conformational equilibrium
depends upon both its own substitution with 2-O-sulfate and
the substitution of neighboring glucosamines by N-sulfation
and 6-O-sulfation (35–37, 52, 53). Sulfate substitutions have
also been shown to influence glycosidic linkage geometry (37,
53), adding a further level of structural flexibility to the polysac-
charide. Protein binding to HS and the coordination of cations
by oxygens in the sugar have also recently been shown to affect
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the conformational characteristics and flexibility ofHS/heparin
(53–55), possibly contributing to the formation of epitope
structures in vivo. Sulfate substitutions on HS chains coupled
with protein binding events and cation coordination will there-
fore influence the conformation and flexibility of the polysac-
charide, ultimately influencing the spatial display of reactive
binding groups, principally sulfate, carboxyl, and hydroxyl
groups, generating structures inHS that are favorable (or inhib-
itory) for antibody binding. Previous reports have focused on
defining linear epitopes with specific sulfation patterns (24, 28,
41). However, the data presented here suggest that epitopes are
more complex than this and are likely to be represented by
more than one combination of sulfation pattern and sugar con-
formation; together these structural characteristics likely create
a specific three-dimensional epitope structure within a HS
chain that fits optimally into an antibody HS-binding site. It is
therefore probable that instead of binding to one definitive HS
motif, antibodies bind to a (somewhat restricted) class of struc-
turally relatedHS epitopeswhose sequences present sulfate and
carboxyl groups to the antibody in a more (higher affinity) or
less (lower affinity) optimal geometry.
Interpretation of in Situ and inVitro BindingData—Discrep-
ancies between epitope levels observed in fetal rat lungs in situ
and in vitro highlight the need for caution when interpreting
antibody binding data and, indeed, data using other heparin-
binding proteins. A number of epitopes that were only weakly
identified in fetal lungs in situ were measurable at an apparent
high level in lung extracts by dot blotting. Most dramatically,
the HS4C3V epitope was detected at a high level in lung
extracts (Fig. 2) but was not identified at all in lung immuno-
histochemistry (data not shown). This may be due to occupa-
tion of epitopes in situ by HS-binding proteins, i.e. the epitopes
are cryptic, making them unavailable for antibody recognition.
This may arise directly, whereby endogenous proteins occupy
an antibody epitope, or indirectly, whereby endogenous pro-
teins bound to HS modify the conformation of an adjacent
epitope. Epitopes that in situ aremasked byHS-bound proteins
will become available in lung extracts containing the ionic
detergent SDS, which will release many of the proteins bound
to HS. Conversely, epitopes that appear at a low level in lung
extracts but are present at a high level in situmay be generated
in HS chains in situ by protein binding and/or cation coordina-
tion to HS, which will alter sugar conformation and therefore
potentially promote conformations in weak epitopes that are
favorable for antibody binding. These epitopes will therefore be
diminished in vitro via removal of bound proteins and/or alter-
ation of coordinated cations. These data support the view that
the antibody epitopes are highly complex and dependent upon
multiple factors. Thus, in situ patterns of antibody binding
likely reflect a combination of availability of appropriate under-
lyingHS structures and the overlying presence of other binding
proteins, creating a dynamic landscape for functional epitope
expression. This notion is supported by in situ studies with
other HS-binding proteins using the LACE technique (56). An
important implication is that caution must be exercised to
avoid overly simplistic interpretation of in situ binding data.
This has been noted previously, where immunocytochemical
detection of fibroblast growth factor in developing mammary
glands suggested the presence of cryptic fibroblast growth fac-
tor-binding sites inHS in situ (57). Our data also suggest that in
future studies, the exploitation of targetedwashing and binding
conditions of varying stringencywithin in situ experimentsmay
permit novel insights into the dynamics of HS epitope expres-
sion to be obtained.
Selectivity of HS-Protein Interactions—HS phage display
antibodies essentially represent a panel of HS-binding proteins
of similar structure and surface electrostatics, the major differ-
ence between them being a 6–11-amino acid VH CDR3
sequence. They are therefore useful model proteins for investi-
gating the selectivity of HS-protein interactions in general.
Interestingly, we noted for the first time that, with the excep-
tion of HS3B7V, the highly basic antibody structures are virtu-
ally identical. Nonetheless, the binding specificities of individ-
ual antibodies in immunohistochemistry and competitive
binding assays are unique, suggesting that HS-protein interac-
tions are not simply electrostatically driven but rely on a degree
of structural specificity in HS creating specific contacts
between protein and polysaccharide via hydrogen and van der
Waals bonding. This emphasizes the need for caution when
affinity selection of the antibodies is used to identify sugar bind-
ing partners (41, 43), because elution by increasing ionic
strength is likely to bias toward simpler ionic bonding. Impor-
tantly, this applies more broadly to HS-protein binding studies,
which are often analyzed using this approach, despite signifi-
cant evidence for the importance of nonionic interactions (58–
60). This suggests that an approach examining alternative
selection modes could be a productive area of future study.
Overall, it is also highly likely that in vivo, a particular HS-
binding protein is able to bind more than one HS motif, with
subtle alterations in sulfation pattern and sugar conformation
influencing the affinity of interaction, thereby regulating the
activity of the protein ligand. This view is supported by the vast
majority of previous data for this class of glycan-protein inter-
action, including the prototypic antithrombin III-binding site.
Despite the latter often being viewed as a single pentasaccha-
ride sequence, there are a number of variants of this structure
that still permit significant binding and activity, indicating a
degree of permissible variation around what constitutes a con-
sensus bioactive binding site (61–66). Altering the conforma-
tion of heparin, e.g. by coordination of different cations, has
been shown to modify polysaccharide biological activity (53),
presumably by altered interactions with cellular proteins. Ena-
bling a protein to bind multiple HS structures allows HS to
regulate multiple cellular activities of an individual protein, e.g.
formation of protein gradients, transport of a protein from the
site of production to a target cell, retention of proteins in the
extracellular matrix, and formation of active cell surface signal-
ing complexes. Transport of HS-binding proteins through the
extracellularmatrix to a target cell, for example, is likely to involve
sequential binding todifferentHSchains andmovement from low
affinity to higher affinity binding structures as suggested previ-
ously by analysis of mammary cell-derived HS (67).
In summary, phage display antibodies are useful tools for
analyzing native HS in situ, identifying distinct families of HS
motifs. In situ, antibody epitope structures will be generated by
specific patterns of sulfation and also sugar conformation,
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which is influenced by sulfate substitutions in and around the
epitope, coordination of cations, and protein binding events
near the epitope and also atmore distant sites along aHS chain.
TheHSphage display antibodies provide amodel system that
generates important insights that likely reflect the specificity of
HS-protein interactions in vivo and highlights the complexity
of the relationship between proteins and HS-binding motifs.
An individual protein is able to bind to multiple HS sequences,
with dynamic variations in sulfation and conformation altering
the affinity of interaction. This provides a subtlemechanism for
regulating the cellular activities of biologically important HS-
binding proteins.
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61. Lindahl, U., Bäckström, G., Höök, M., Thunberg, L., Fransson, L. A., and
Linker, A. (1979) Proc. Natl. Acad. Sci. U.S.A. 76, 3198–3202
62. Atha, D.H., Stephens, A.W., andRosenberg, R. D. (1984)Proc. Natl. Acad.
Sci. U.S.A. 81, 1030–1034
63. Hovingh, P., Piepkorn, M., and Linker, A. (1986) Biochem. J. 237,
573–581
64. Petitou, M., Lormeau, J. C., and Choay, J. (1988) Eur. J. Biochem. 176,
637–640
65. Guerrini, M., Guglieri, S., Casu, B., Torri, G., Mourier, P., Boudier, C., and
Viskov, C. (2008) J. Biol. Chem. 283, 26662–26675
66. Chen, J., Jones, C. L., and Liu, J. (2007) Chem. Biol. 14, 986–993
67. Rahmoune, H., Chen, H. L., Gallagher, J. T., Rudland, P. S., and Fernig,
D. G. (1998) J. Biol. Chem. 273, 7303–7310
Complex Binding Characteristics of HS scFv Antibodies
















Supplementary Figure S1. Proposed model and surface electrostatic potential of HS3A8V from four 
different perspectives. A large proportion of basic residues are observed on the surface of the antibody 
which will interact with HS and heparin, two possible HS binding axes and their length are shown. 
Regions of positive surface charge are represented in blue and regions of negative charge are in red, while 
neutral areas are white. 
 
Supplementary Figure S2. Proposed model and surface electrostatic potential of EV3C3V from 
four different perspectives. A large proportion of basic residues are observed on the surface of the 
antibody which will interact with HS and heparin, two possible HS binding axes and their length are 
shown. Regions of positive surface charge are represented in blue and regions of negative charge are in 
red, while neutral areas are white. 
 
Supplementary Figure S3. Proposed model and surface electrostatic potential of EW4G1V from 
four different perspectives. A large proportion of basic residues are observed on the surface of the 
antibody which will interact with HS and heparin, two possible HS binding axes and their length are 
shown. Regions of positive surface charge are represented in blue and regions of negative charge are in 
red, while neutral areas are white. 
 
Supplementary Figure S4. Proposed model and surface electrostatic potential of AO4BO8V from 
four different perspectives. A large proportion of basic residues are observed on the surface of the 
antibody which will interact with HS and heparin, two possible HS binding axes and their length are 
shown. Regions of positive surface charge are represented in blue and regions of negative charge are in 
red, while neutral areas are white. 
 
Supplementary Figure S5. Binding of HS antibodies to immobilised HS in the presence of heparin 
oligosaccharides of various length. PMHS was biotinylated and immobilised on streptavidin-coated 
microtiter plates. Equilibrium binding of HS antibodies in the presence of heparin oligosaccharides was 
quantified at A490 using an anti-VSV-G tag antibody (P5D4) followed by HRP conjugated anti-mouse 
antibody and OPD substrate.  
The range of heparin lengths were dp2     dp4      dp6    dp8                  
dp10    and full length heparin     . For HS3B7V, the range of heparin oligosaccharide 
lengths was extended to include dp12   dp14    dp16     dp18                  
and dp20  . Values are shown as % inhibition and are the mean of triplicate samples, error bars 
represent the S.E and the data are representative of two separate experiments. 
 
Supplementary Figure S6. Binding of HS antibodies to immobilised HS in the presence of heparin, 
HS and various heparin analogues. PMHS was biotinylated and immobilised on streptavidin-coated 
microtiter plates. Equilibrium binding of HS antibodies in the presence of heparin analogues were 
quantified at A490 using an anti-VSV-G tag antibody (P5D4) followed by HRP conjugated anti-mouse 
antibody and OPD substrate. 
Polysaccharides;    Heparin                        HS                      de-N-sulfated/N-acetylated heparin   
de-2-O-sulfated heparin                     de-6-O-sulfated heparin                      de-2-O/de-N-sulfated/N-
acetylated heparin                    de-6-O/de-N-sulfated/N-acetylated heparin                 .   Values are 
shown as % inhibition and are the mean of triplicate samples, error   bars   represent the  S.E and the data 
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